October 25, 2001
Gayle Edlund Wilson Joins Gilead Sciences Board of Directors
Foster City, CA -- October 25, 2001
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Gayle Edlund Wilson has been appointed to the company's Board of Directors, bringing the number of directors to eight. Mrs. Wilson also will serve on the Compensation Committee of the Board of Directors. Mrs. Wilson's career has primarily focused on volunteerism, early childhood health and math and science education.
Wife of former California Governor Pete Wilson, Mrs. Wilson, served as California's First Lady from 1991-1999. During this time, she helped to establish the California State Summer School for Math and Science (COSMOS) program, an academic summer program for talented and motivated students completing grades 8-12, and continues to be a member of the Advisory Board. Mrs. Wilson currently serves as a director of Chela Financial, Inc., a nonprofit corporation providing financial assistance to students pursuing higher education, and the Ralph M. Parsons Foundation, a nonprofit organization providing grants primarily in the areas of higher education, social impact, civic and cultural, and health. She also serves as an advisor for BroadDaylight, Inc., a leading provider of software designed to streamline Web-based customer service functions. In addition, Mrs. Wilson is a trustee of the California Institute of Technology (Caltech) and a member of its Jet Propulsion Lab Committee.
"We are very pleased to welcome Gayle Wilson to the Gilead Sciences Board of Directors," said James M. Denny, Chairman of Gilead's Board of Directors. "Mrs. Wilson's career in education, public policy and science and technology will benefit Gilead in its efforts to develop and commercialize new medicines for life-threatening diseases."
Gilead Sciences, Inc., headquartered in Foster City, CA, is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. Gilead discovers, develops, manufactures and commercializes proprietary therapeutics for challenging infectious diseases (viral, fungal and bacterial infections) and cancer. Gilead maintains research, development or manufacturing facilities in the United States, Europe and Australia.